Effectiveness and Safety of Antiretroviral Treatment in Pre- and Postmenopausal Women Living with HIV in a Multicentre Cohort. Issue 6 (August 2020)

• Record Type: Journal Article
• Authors: Alejos, Belén; Suárez-García, Inés; Bernardino, Jose Ignacio; Blanco, José Ramón; Peñaranda, Maria; Bautista, Azucena; Gutiérrez, Félix; Jarrín, Inma; Hernando, Victoria
• Is Part Of: Antiviral therapy. Volume 25:Issue 6(2020)
• Page Start: 335
• Page End: 340
• Publication Date: 2020-08
• Subjects: Antiviral agents -- Periodicals; Antiviral Agents -- therapeutic use; Virus Diseases -- therapy; Viruses -- drug effects; Antiviral agents; Periodical; Electronic journals; Periodicals; 616.9106
• DOI: 10.3851/IMP3380
• Languages: English
• ISSNs: 1359-6535

Abstract

Background: To compare effectiveness and safety of initial antiretroviral therapy (ART) among premenopausal and postmenopausal women living with HIV aged 45–60 years from the cohort of the Spanish HIV/AIDS Research Network (CoRIS) who initiated ART between 2004 and 2015. Methods: Multivariable regression models were used to compare post- versus premenopausal women regarding viral suppression (≤50 copies/ml), change in CD4 + T-cell count and time to treatment change (TC) at 48 and 96 weeks after ART initiation. Results: Among 230 women, 154 (67%) were premeno-pausal at ART initiation. The most frequent initial regimen was tenofovir disoproxil fumarate/emtricitabine/efavirenz prescribed in 49 (32%) premenopausal and 22 (29%) postmenopausal women. The proportion of TC was 35.7% and 30.3% at 48 weeks and 51.3% and 47.4% at 96 weeks, for pre- and postmenopausal women, respectively. There were no significant differences in CD4 + T-cell count changes from ART initiation, viral load suppression, time to TC or reason for TC between both groups. The main reason for TC was occurrence of an adverse event, followed by simplification, in both groups. Conclusions: ART effectiveness and safety did not differ significantly between pre- and postmenopausal women.